Cliff Asness's BBIO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 98,827 shares of BridgeBio Pharma, Inc. (BBIO) worth $5.13 M, representing 0.00% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in BBIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 96,926 shares. Largest reduction occurred in Q1 2025, reducing 89,316 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's BridgeBio Pharma (BBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Pharma (BBIO) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2020 | +46,725 | New Buy | 46,725 | $32.62 |
| Q3 2020 | -40,976 | Reduce 87.70% | 5,749 | $37.57 |
| Q4 2020 | -1,848 | Reduce 32.14% | 3,901 | $71.01 |
| Q1 2021 | +13,989 | Add 358.60% | 17,890 | $61.60 |
| Q2 2021 | -10,122 | Reduce 56.58% | 7,768 | $61.02 |
| Q3 2021 | +7,917 | Add 101.92% | 15,685 | $46.86 |
| Q4 2021 | -15,685 | Sold Out | 15,685 | $0.00 |
| Q2 2023 | +25,824 | New Buy | 25,824 | $17.20 |
| Q3 2023 | -3,622 | Reduce 14.03% | 22,202 | $26.37 |
| Q4 2023 | +10,832 | Add 48.79% | 33,034 | $40.37 |
| Q1 2024 | +96,926 | Add 293.41% | 129,960 | $30.92 |
| Q2 2024 | -4,800 | Reduce 3.69% | 125,160 | $25.33 |
| Q3 2024 | +70,803 | Add 56.57% | 195,963 | $25.46 |
| Q4 2024 | +27,610 | Add 14.09% | 223,573 | $27.44 |
| Q1 2025 | -89,316 | Reduce 39.95% | 134,257 | $34.57 |
| Q2 2025 | +23,548 | Add 17.54% | 157,805 | $43.18 |
| Q3 2025 | -58,978 | Reduce 37.37% | 98,827 | $51.94 |
Cliff Asness's BridgeBio Pharma Investment FAQs
Cliff Asness first purchased BridgeBio Pharma, Inc. (BBIO) in Q2 2020, acquiring 46,725 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held BridgeBio Pharma, Inc. (BBIO) for 22 quarters since Q2 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q1 2024, adding 129,960 shares worth $4.02 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 98,827 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $5.13 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in BridgeBio Pharma, Inc. (BBIO) was 223,573 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.